US FDA action on unapproved codeine will not hit Glenmark's financials, firm says
This article was originally published in Scrip
The US FDA's recent warning to four companies asking them to stop marketing unapproved codeine sulphate tablets is expected to have no significant impact on Glenmark's financial performance, the firm said.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.